Literature DB >> 6193228

Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies.

M L Egan, D G Pritchard, H C Dillon, B M Gray.   

Abstract

Mouse hybridoma antibodies of several major classes against group B streptococcus type III have been produced. Mice were immunized with either whole heat-killed or acid-treated organisms to obtain antibodies against both the complete (sialated) or incomplete (nonsialated) forms of the type III polysaccharide. Resulting monoclonal antibodies showed exclusive specificity for either the complete or incomplete antigen. The ability of these antibodies to protect mice from a lethal challenge of live type III organisms was tested with a mucin model that permitted use of very small inocula given intraperitoneally with antibody and mucin. Antibodies specific for the nonsialated antigen were not protective, whether of IgM, IgG2a, or IgG3 isotypes. Antibodies specific for the complete antigen were, however, highly protective, including monoclonals of IgM, IgG2a, and IgA isotypes. These mouse monoclonal antibodies against group B streptococci that are directed against either complete or incomplete antigenic determinants, and include isotypes other than IgM, should be particularly useful for studying the mechanism of protection against experimental infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193228      PMCID: PMC2187106          DOI: 10.1084/jem.158.3.1006

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  Type-specific polysaccharide antigens of group B streptococci.

Authors:  R C Lancefield; E H Freimer
Journal:  J Hyg (Lond)       Date:  1966-06

3.  Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus.

Authors:  H J Jennings; K G Rosell; D L Kasper
Journal:  Can J Biochem       Date:  1980-02

4.  Immunochemistry of purified polysaccharide type antigens of group B streptococcal types Ia, Ib, and Ic.

Authors:  H W Wilkinson
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

5.  ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes.

Authors:  B M Gray
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

6.  Mucin model for group B type III streptococcal infection in mice.

Authors:  D O Fleming
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

7.  Isolation of type-specific polysaccharide antigen from group B type Ib streptococci.

Authors:  J Y Tai; E C Gotschlich; R C Lancefield
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

8.  Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.

Authors:  G W Fischer; G H Lowell; M H Crumrine; J W Bass
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

9.  Immunodeterminant specificity of human immunity to type III group B streptococcus.

Authors:  D L Kasper; C J Baker; R S Baltimore; J H Crabb; G Schiffman; H J Jennings
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307

10.  IgA-dependent, monocyte-mediated, antibacterial activity.

Authors:  G H Lowell; L F Smith; J M Griffiss; B L Brandt
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  18 in total

1.  Capsular sialic acid limits C5a production on type III group B streptococci.

Authors:  S Takahashi; Y Aoyagi; E E Adderson; Y Okuwaki; J F Bohnsack
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  The potential use of monoclonal antibodies as therapeutic modalities in neonatal infection.

Authors:  H R Hill; L A Gonzales; D K Kelsey; H V Raff
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

3.  Preservation of capsular material of streptococcal cells by specific lectins determined by immunoelectron microscopy.

Authors:  A Molinari; G Orefici; G Donelli; C Von Hunolstein; S Paradisi; G Arancia
Journal:  Histochem J       Date:  1988-09

4.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 5.  Monoclonal antibodies for the diagnosis of infectious diseases.

Authors:  M C Harris
Journal:  Indian J Pediatr       Date:  1987 Jul-Aug       Impact factor: 1.967

Review 6.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

Review 7.  Monoclonal antibodies against microorganisms.

Authors:  R A Polin
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

8.  Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci.

Authors:  B F Anthony; N F Concepcion; C A Wass; D C Heiner
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

9.  Murine monoclonal antibodies to type Ib polysaccharide of group B streptococci bind to human milk oligosaccharides.

Authors:  D G Pritchard; B M Gray; M L Egan
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

10.  Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes.

Authors:  E Lett; S Gangloff; M Zimmermann; D Wachsmann; J P Klein
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.